• Access To Medicines

LifeArc Joins Forces with Cystic Fibrosis Trust and Medicines Discovery Catapult to Strengthen Antimicrobial Discovery Efforts

Pivotal partnership seeks to transform Cystic Fibrosis research.

Landmark partnership aims to improve Scotland’s health

A ground-breaking collaboration between NHS, university and industry partners has been launched to co-create NHS Scotland transformation through large scale programmes to improve the health of the population and expand clinical research.

Cancer researchers taking the MYC

Cancer researchers taking the MYC (pronounced Mick) is an oncogene – a gene that when deregulated can contribute to formation of cancer. Many things are known about the Myc protein produced from this gene: that it interacts with DNA to switch on/off many other genes (about 15% of all genes!), and in turn it orchestrates several (more than 10) cellular processes. But when there’s too much of it, it helps cancers to develop, and this is a key feature of more than half of all cancers in humans. But we still don’t know enough about it.

Medicines Discovery Catapult and ZEISS Set Sights on Advancing Microscopy

Medicines Discovery Catapult (MDC) and ZEISS have joined forces to improve drug discovery and early development of complex medicines by harnessing the power of advanced microscopy solutions.

Cell and Gene Therapy Catapult and the UK Dementia Research Institute announce collaboration to accelerate advancements in gene therapy

The Cell and Gene Therapy Catapult (CGT Catapult) and the UK Dementia Research Institute (UK DRI) today announce a collaboration to accelerate the clinical development of adeno-associated virus (AAV) based gene therapies for dementia.

Revolutionary new oral medicine to treat inflammatory bowel disease developed by industry collaboration

An innovative capsule could take the gold-standard treatment for Crohn’s disease and ulcerative colitis out of hospital and into patients’ homes for the first time. The oral infliximab drug delivery system was developed by a collaboration between Intract Pharma, Pharmidex, Quay Pharma and deep tech innovation organisation CPI.

RQ Bio launches with goal to transform treatment and prevention of viral infection diseases through antibody technologies

UK-based RQ Biotechnology Ltd (RQ Bio) launches with funding from licensing deal with AstraZeneca for RQ Bio’s existing early stage monoclonal antibodies (mAbs) against SARS-CoV-2 with payments of up to $157 million plus royalties.

EuropaBio published policy recommendations for the healthcare and industrial biotechnology sectors

EuropaBio has published the National Associations Council Summit 2022 Event Report ''Biotechnology: Delivering Europe’s industrial strategy across the sectors''. The report includes key policy recommendations for healthcare and industrial biotechnology sectors at national and the EU level which could serve the policymakers to get a better understanding of the sector’s potential and regulatory challenges in operating on the national and EU level.

Making the Innovative Medicines Fund work for the most innovative new medicines

The ultimate aim of drug development is for patients to access lifesaving and life-enhancing new medicines, but for many of the most innovative new medicines, securing access for NHS patients is a long and difficult process. One of the most promising new areas of medicine is cell and gene therapies, which have potential to address complex diseases, including many rare diseases for which there are no effective treatments. However, these treatments face challenges in securing patient access because of high up-front cost and uncertainty about long-term outcomes.

Life Science Group transfers operations to new facility in Sandy, Bedfordshire

Life Science Group (LSG) is a privately owned biologicals manufacturing company producing contract manufacturing solutions for a variety of Life Science applications.